Table 1.
The characteristics of patients and healthy controls.
| Characteristics | MM | HC |
|---|---|---|
| Gender | ||
| Male | 14 (43.75 %) | 16 (53.33 %) |
| Female | 18 (56.25 %) | 14 (46.67 %) |
| Age (years) | ||
| Mean (SD) | 59.34 (9.18) | 60.53 (10.89) |
| Median (Range) | 59 (39–84) | 58 (40–80) |
| Leukocytes (x109/L) | ||
| Mean (SD) | 8.69 (4.21) | |
| Median (Range) | 7.65 (3.6–20.7) | |
| Lymphocytes (x109/L) | ||
| Mean (SD) | 1.53 (0.64) | |
| Median (Range) | 1.60 (0.5–2.8) | |
| Neutrophils (x109/L) | ||
| Mean (SD) | 6.00 (3.60) | |
| Median (Range) | 5.00 (2.4–18.4) | |
| Performance status | ||
| 0 | 11 (34.37 %) | |
| 1 | 10 (31.25 %) | |
| 2 | 7 (21.88 %) | |
| 3 | 4 (12.50 %) | |
| 4 | 0 (0 %) | |
| Metastasis stage | ||
| M1a | 2 (6.25 %) | |
| M1b | 10 (31.25 %) | |
| M1c | 12 (37.5 %) | |
| M1d | 8 (25 %) | |
| Immune-related adverse events | ||
| Hepatotoxicity | 1 (3.12 %) | |
| Eosinophilia | 1 (3.12 %) | |
| Hypothyroidism | 1 (3.12 %) | |
| Hyperbilirubinemia | 1 (3.12 %) | |
| Neutropenia | 1 (3.12 %) | |
| Baseline LDH | ||
| Normal | 20 (62.50 %) | |
| Elevated | 12 (37.50 %) | |
| AST (U/L) | ||
| Mean (SD) | 25.62 (17.85) | |
| Median (Range) | 19.50 (10–88) | |
| ALT (U/L) | ||
| Mean (SD) | 24.78 (21.56) | |
| Median (Range) | 17.5 (9–108) | |
| γ-GT (U/L) | ||
| Mean (SD) | 48.37 (48.12) | |
| Median (Range) | 33.50 (10–203) | |
| Pembrolizumab cycles | ||
| Mean (SD) | 29.28 (24.19) | |
| Median (Range) | 26.5 (1–68) | |
| Therapy responses | ||
| Non-DP | 14 (43.75 %) | |
| CR | 6 (42.86 %) | |
| PR | 5 (35.71 %) | |
| SD | 3 (21.43 %) | |
| DP | 18 (56.25 %) | |
| Total | 32 (100 %) | 30 (100 %) |